Vanda Pharmaceuticals (NASDAQ:VNDA) Lifted to Buy at StockNews.com

StockNews.com upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) from a hold rating to a buy rating in a report issued on Thursday. Vanda Pharmaceuticals Stock Performance Vanda Pharmaceuticals stock opened at $3.76 on Thursday. The firm has a market cap of $216.31 million, a price-to-earnings ratio of 17.91 and a beta of 0.59. […]

Related Keywords

,Lido Advisors ,Sherbrooke Park Advisers ,Tower Research Capital ,Quadrant Capital Group ,Vanda Pharmaceuticals ,Vanda Pharmaceuticals Inc ,Vanda Pharmaceuticals Company Profile ,Vanda Pharmaceuticals Stock Performance ,News Ratings For Vanda Pharmaceuticals Daily ,Free Report ,Capital Group ,Research Capital ,Get Free Report ,Pharmaceuticals Inc ,Vanda Pharmaceuticals Daily ,Nasdaq Vnda ,Vnda ,Medical ,92165910 ,Upgrade ,Stocknews Com ,